Bionical Emas to further strengthen its position as a market leader in Early Access Programs and Clinical Trial Supply The Company will invest in ...

EMAS Pharma strongly positioned as a leading independent CRO in fast-growing and global marketHighly experienced Board and Executive Team put in ...

SMi Reports: Interview excerpt with Bionical EMAS’ Executive VP, Tom Watson released for SMi’s 9th Annual Conference on Orphan Drugs & Rare Diseases, in London in less than 3 weeks With less ...

UK-based private equity firm Kester Capital has acquired EMAS Pharma, the clinical development division of Bionical Emas, ...

LONDON, Dec. 09, 2024 (GLOBE NEWSWIRE) -- Bionical Emas (“Bionical”) or (“the Company”), the Early Access Programs and Clinical Trial Supply business, is selling its Clinical Development ...

Kester and the new executive team are buying the business from Bionical for an undisclosed sum. Following a strategic review, Bionical will now focus its business on Early Access Programs and ...

Bionical Emas to further strengthen its position as a market leader in Early Access Programs and Clinical Trial Supply The Company will invest in global expansion and further specialised services ...